Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - SR3
SR3 Details
Status: Closed 
Activation Date: 1999OCT05
Closing Date: 2003DEC15
Phase: III 

Description: Randomized Trial of Adjuvant Chemotherapy with High-dose Doxorubicin, Ifosfamide and Lenograstim (G-CSF) in High Grade Soft Tissue Sarcoma 

Eligibility: Patients with histologically proven high grade soft tissue sarcoma (grade II or III) with no evidence of metastases. 

Objective: To compare the effect of treatment with ifosfamide and high dose doxorubicin with filgrastim versus observation on overall survival and relapse free survival. 

Participation: Not limited 

Lay Description: The purpose of the study is to find out whether it is better to receive chemotherapy after standard therapy or standard therapy alone. To do this, half of the patients in the study will get doxorubicin, ifosfamide, G-CSF (filgrastim) with standard therapy, and the other half will receive standard therapy only. Standard therapy is surgery to remove the tumor and in some cases radiation is added as well. 

Primary Publication Show

Other Publications Show

Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
SARCOMA SR3 13 0 0 0
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
SARCOMA SR3 13 0 0
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
SARCOMA SR3 13 0 0 0 0 0 0 0 0